When Zontivity® was shelved last month, we knew this day would come. It merits scant mention — as it is not remotely material.
Here is the Reuters news brief, of early this morning, just the same — for a complete record:
. . . .Aralez says asset purchase agreement entered into between Merck, and Aralez Pharmaceuticals Trading DAC, unit of Aralez. . .
Asset purchase agreement included an initial upfront payment of $25 million, which was paid from cash on hand. . .
Product rights, packaging, labeling and other responsibilities transferred to Aralez Pharmaceuticals. . .
Onward — quite a come-down.